ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.425,73
0,85%
S&P 500
5.998,74
-0,38%
Dow Jones
44.722,06
-0,31%
Euro vs US Dollar
1,05684
0,07%
Bitcoin
96.783,34
1,18%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Belite Bio Inc (BLTE)

  7. Belite Bio Inc (BLTE) News

BLTE

Belite Bio (BLTE)

Belite Bio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BLTE
DatumZeitQuelleÜberschriftSymbolFirma
27/11/202409h00GlobeNewswire Inc.Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007NASDAQ:BLTEBelite Bio Inc
21/11/202400h25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
20/11/202400h17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
12/11/202407h00GlobeNewswire Inc.Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:BLTEBelite Bio Inc
05/11/202414h00GlobeNewswire Inc.Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
04/11/202412h02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLTEBelite Bio Inc
03/11/202422h00GlobeNewswire Inc.Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross ProceedsNASDAQ:BLTEBelite Bio Inc
14/10/202414h00GlobeNewswire Inc.Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual MeetingNASDAQ:BLTEBelite Bio Inc
08/10/202423h48Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:BLTEBelite Bio Inc
08/10/202423h46Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:BLTEBelite Bio Inc
08/10/202414h00GlobeNewswire Inc.Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual SummitNASDAQ:BLTEBelite Bio Inc
04/10/202402h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
04/10/202402h48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
01/10/202412h03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BLTEBelite Bio Inc
26/09/202414h51GlobeNewswire Inc.Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online ViewingNASDAQ:BLTEBelite Bio Inc
20/09/202418h40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
17/09/202417h22GlobeNewswire Inc.International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024NASDAQ:BLTEBelite Bio Inc
10/09/202414h00GlobeNewswire Inc.Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt DiseaseNASDAQ:BLTEBelite Bio Inc
04/09/202418h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
03/09/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLTEBelite Bio Inc
03/09/202414h00GlobeNewswire Inc.Belite Bio to Participate in Three Upcoming Investor ConferencesNASDAQ:BLTEBelite Bio Inc
01/09/202414h00GlobeNewswire Inc.Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical OfficerNASDAQ:BLTEBelite Bio Inc
17/08/202400h24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
14/08/202422h32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
14/08/202422h30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
14/08/202420h38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
09/08/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLTEBelite Bio Inc
09/08/202422h30GlobeNewswire Inc.Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateNASDAQ:BLTEBelite Bio Inc
08/08/202414h00GlobeNewswire Inc.Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceNASDAQ:BLTEBelite Bio Inc
06/08/202401h10GlobeNewswire Inc.Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
 Showing the most relevant articles for your search:NASDAQ:BLTE

Kürzlich von Ihnen besucht

TG
CBK
Commerzbank
TG
RHM
Rheinmetall
NASDAQ
AAPL
Apple
TG
DBK
Deutsche Bank
PM
XAUUSD
Gold vs US Dollar
NYSE
MCD
McDonalds
CCOM
SILVER
SILVER
COIN
SOLUSD
Solana
NYSE
JPM
JP Morgan Chase
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
AMZN
Amazon.com
AMEX
XLE
Energy Select Sector SPDR
NYSE
NKE
Nike
NYSE
KO
Coca Cola
NASDAQ
MSFT
Microsoft
TG
D7G
Nel ASA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten

BLACK FRIDAY

ADVFN

Seit 25 Jahren im Geschäft 1999-2024

Sparen Sie bis zu 60%* für Euronext Level 2

1 Jahr 40%, 2 Jahre 50% und *3 Jahre 60%

*Über 3 Jahre 1094.04€, jetzt nur noch 437.62€